Screener
Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Amounts | Amounts |
|---|---|---|
| Thereafter | 15,396 | |
| Total future lease payments, undiscounted | 27,654 | |
| (Less): Imputed interest | (11,014) | |
| (Less): Tenant improvement allowance | (591) | |
| Present value of operating lease payments | $ | $16,049 |
| Operating lease liability, current | 154 | |
| Operating lease liability, non-current | 15,895 | |
| Total operating lease liability | $ | $16,049 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liabilities?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liabilities of $15.9M in Q2 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities has grown at a 80.8% compound annual growth rate (CAGR), from $549K to $10.6M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude